Platelet Mediated TRAIL Delivery for Efficiently Targeting Circulating Tumor Cells

Overview

Journal Nanoscale Adv

Publisher Royal Society of Chemistry

Specialty Biotechnology

Date 2022 Sep 22

PMID 36132797

Authors

Nerymar Ortiz-Otero

Jocelyn R Marshall

Bradley W Lash

Michael R King

Affiliations

Soon will be listed here.

Abstract

Several studies have demonstrated the role of platelets in promoting cancer metastasis. Platelets bind to and protect circulating tumor cells (CTCs) from hemodynamic forces and immune cells, and also promote tumor cell arrest in the vasculature and extravasation. Thus, platelets represent a promising vehicle to deliver anticancer therapeutic agents to CTCs. In this study, we developed a novel platelet-mediated TNF-related apoptosis inducing ligand (TRAIL) delivery system to target CTCs and hinder metastasis "" platelet modification. This platelet-mediated TRAIL delivery significantly reduced the viability of colorectal and breast cancer cells circulating in flowing blood under physiological shear conditions. TRAIL-coated platelets significantly killed over 60% of CTCs in flowing blood from a variety of primary metastatic cancer samples. Platelets have been considered an important player in the regulation of metastasis due to their interaction with cancer cells in the circulation; the current study supports the idea of using platelet-based TRAIL delivery as a promising CTC-targeted cancer therapy.

Citing Articles

Theoretical basis, state and challenges of living cell-based drug delivery systems.

Liu W, Cheng G, Cui H, Tian Z, Li B, Han Y Theranostics. 2024; 14(13):5152-5183.

PMID: 39267776 PMC: 11388066. DOI: 10.7150/thno.99257.

Advances in circulating tumor cells for early detection, prognosis and metastasis reduction in lung cancer.

Wang X, Bai L, Kong L, Guo Z Front Oncol. 2024; 14:1411731.

PMID: 38974237 PMC: 11224453. DOI: 10.3389/fonc.2024.1411731.

Dual Affinity Nanoparticles for the Transport of Therapeutics from Carrier Cells to Target Cells under Physiological Flow Conditions.

Lopez-Cavestany M, Wright O, Cassidy A, Carter A, King M ACS Omega. 2023; 8(45):42748-42761.

PMID: 38024679 PMC: 10652824. DOI: 10.1021/acsomega.3c05605.

Platelet-promoting drug delivery efficiency for inhibition of tumor growth, metastasis, and recurrence.

Li X, Hu L, Tan C, Wang X, Ran Q, Chen L Front Oncol. 2022; 12:983874.

PMID: 36276066 PMC: 9582853. DOI: 10.3389/fonc.2022.983874.

Lipid Phase Separation in Vesicles Enhances TRAIL-Mediated Cytotoxicity.

Vu T, Peruzzi J, SantAnna L, Roth E, Kamat N Nano Lett. 2022; 22(7):2627-2634.

PMID: 35298184 PMC: 9680886. DOI: 10.1021/acs.nanolett.1c04365.

References

Xu P, Zuo H, Zhou R, Wang F, Liu X, Ouyang J . Doxorubicin-loaded platelets conjugated with anti-CD22 mAbs: a novel targeted delivery system for lymphoma treatment with cardiopulmonary avoidance. Oncotarget. 2017; 8(35):58322-58337. PMC: 5601655. DOI: 10.18632/oncotarget.16871. View

Niers T, Klerk C, DiNisio M, van Noorden C, Buller H, Reitsma P . Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol. 2006; 61(3):195-207. DOI: 10.1016/j.critrevonc.2006.07.007. View

Papa A, Jiang A, Korin N, Chen M, Langan E, Waterhouse A . Platelet decoys inhibit thrombosis and prevent metastatic tumor formation in preclinical models. Sci Transl Med. 2019; 11(479). DOI: 10.1126/scitranslmed.aau5898. View

Hanahan D, Coussens L . Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012; 21(3):309-22. DOI: 10.1016/j.ccr.2012.02.022. View

Li J, King M . Adhesion receptors as therapeutic targets for circulating tumor cells. Front Oncol. 2012; 2:79. PMC: 3402858. DOI: 10.3389/fonc.2012.00079. View

Barnes J, Nauseef J, Henry M . Resistance to fluid shear stress is a conserved biophysical property of malignant cells. PLoS One. 2012; 7(12):e50973. PMC: 3513308. DOI: 10.1371/journal.pone.0050973. View

Mitchell M, Wayne E, Rana K, Schaffer C, King M . TRAIL-coated leukocytes that kill cancer cells in the circulation. Proc Natl Acad Sci U S A. 2014; 111(3):930-5. PMC: 3903223. DOI: 10.1073/pnas.1316312111. View

Li J, Sharkey C, Huang D, King M . Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood. Cell Mol Bioeng. 2015; 8(1):137-150. PMC: 4361771. DOI: 10.1007/s12195-015-0381-z. View

Ye H, Wang K, Wang M, Liu R, Song H, Li N . Bioinspired nanoplatelets for chemo-photothermal therapy of breast cancer metastasis inhibition. Biomaterials. 2019; 206:1-12. DOI: 10.1016/j.biomaterials.2019.03.024. View

10.

Khan U, Walker A, Baig S, Card T, Kirwan C, Grainge M . Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis. BMC Cancer. 2017; 17(1):747. PMC: 5681811. DOI: 10.1186/s12885-017-3719-1. View

11.

Li J, Sharkey C, Wun B, Liesveld J, King M . Genetic engineering of platelets to neutralize circulating tumor cells. J Control Release. 2016; 228:38-47. PMC: 4828270. DOI: 10.1016/j.jconrel.2016.02.036. View

12.

Yu Y, Zhou X, Liu Y, Ren N, Chen J, Zhao Y . Platelets promote the adhesion of human hepatoma cells with a highly metastatic potential to extracellular matrix protein: involvement of platelet P-selectin and GP IIb-IIIa. J Cancer Res Clin Oncol. 2002; 128(5):283-7. DOI: 10.1007/s00432-002-0325-6. View

13.

Paix A, Antoni D, Waissi W, Ledoux M, Bilger K, Fornecker L . Total body irradiation in allogeneic bone marrow transplantation conditioning regimens: A review. Crit Rev Oncol Hematol. 2018; 123:138-148. DOI: 10.1016/j.critrevonc.2018.01.011. View

14.

Ortiz-Otero N, Mohamed Z, King M . Platelet-Based Drug Delivery for Cancer Applications. Adv Exp Med Biol. 2018; 1092:235-251. DOI: 10.1007/978-3-319-95294-9_12. View

15.

Lambert A, Pattabiraman D, Weinberg R . Emerging Biological Principles of Metastasis. Cell. 2017; 168(4):670-691. PMC: 5308465. DOI: 10.1016/j.cell.2016.11.037. View

16.

Fressinaud E, Mazurier C, Meyer D . Molecular genetics of type 2 von Willebrand disease. Int J Hematol. 2002; 75(1):9-18. DOI: 10.1007/BF02981973. View

17.

Junttila M, de Sauvage F . Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013; 501(7467):346-54. DOI: 10.1038/nature12626. View

18.

Gareau A, Brien C, Gebremeskel S, Liwski R, Johnston B, Bezuhly M . Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer. Clin Exp Metastasis. 2018; 35(1-2):25-35. DOI: 10.1007/s10585-018-9874-1. View

19.

Chandrasekaran S, Chan M, Li J, King M . Super natural killer cells that target metastases in the tumor draining lymph nodes. Biomaterials. 2015; 77:66-76. PMC: 4684422. DOI: 10.1016/j.biomaterials.2015.11.001. View

20.

Gay L, Felding-Habermann B . Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011; 11(2):123-34. PMC: 6894505. DOI: 10.1038/nrc3004. View